StockData

Altimmune vs NeOnc Technologies

ALT and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

altAltimmune$1.93−54.7% in 1 yearnthiNeOnc Technologies$4.52−55.4% in 1 year

How ALT and NTHI compare

Altimmune is the larger company, worth 3.2 times as much as NeOnc Technologies ($375M against $117M).

Altimmune scores higher on the StockData Score (4 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALTNTHI
Size and price
Market cap$375M$117M
Share price$1.93$4.52
Change, 1 year−54.7%−55.4%
Change, 5 years−81.7%–
Beta (5Y)1.101.59
Employees135
StockData Score
Total score4 (better)0
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score2 (better)0
Dividend score00
Valuation
P/B0.8×–
FCF yield−20.4%–
Growth
Revenue growth, 5Y average−65.3%–
Profitability
Return on equity−28.9%–
Return on invested capital−90.4%–
Financial health
Debt / equity0.07–
Interest coverage−28.3×−15.7× (better)
Current ratio26.78 (better)0.38
Altman Z-score2.51 (better)−34.17
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−29.3%–
Shareholder yield−29.3%0.00% (better)
Ownership
Held by institutions77.9%12.2%
Held by insiders0.51%60.0%
Insider net buying, 12 months$370K$1.5M (better)
Superinvestors holding1–
Short interest, % of float21.8%8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.